Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine
暂无分享,去创建一个
A. Brandes | A. von Deimling | O. Chinot | W. Wick | S. Kesari | D. Capper | S. Estrem | J. Steinbach | H. Wheeler | A. Cleverly | A. Carpentier | D. Desaiah | I. Gueorguieva | M. Lahn | S. Guba | Colin P Miles | P. Specenier | L. Cher | Claire L Smith | J. Sepúlveda-Sánchez | Colin Miles | J. Rodón | Colin P. Miles
[1] G. Reifenberger,et al. Limited role for transforming growth factor-β pathway activation-mediated escape from VEGF inhibition in murine glioma models. , 2016, Neuro-oncology.
[2] A. Brandes,et al. A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. , 2016, Neuro-oncology.
[3] R. Kaaks,et al. Treg-Mediated Immune Tolerance and the Risk of Solid Cancers: Findings From EPIC-Heidelberg. , 2015, Journal of the National Cancer Institute.
[4] K. Kelsey,et al. Serum macrophage‐derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time , 2015, International journal of cancer.
[5] S. Estrem,et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway , 2015, Drug design, development and therapy.
[6] M. Weller,et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. , 2015, Neuro-oncology.
[7] Steven J. M. Jones,et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.
[8] G. De Velasco,et al. Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate. , 2015, Oncology letters.
[9] M. Weller,et al. Transforming growth factor-β pathway activity in glioblastoma , 2015, Oncotarget.
[10] J. Baselga,et al. First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma , 2014, Clinical Cancer Research.
[11] G. Reifenberger,et al. MGMT testing—the challenges for biomarker-based glioma treatment , 2014, Nature Reviews Neurology.
[12] S. Pileri,et al. A novel immunohistochemical classifier to distinguish Hodgkin lymphoma from ALK anaplastic large cell lymphoma , 2014, Modern Pathology.
[13] J. Zimmer,et al. Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level , 2013, Journal of Neuroimmunology.
[14] Alex M. Fichtenholtz,et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.
[15] D. Wainwright,et al. Targeting Tregs in Malignant Brain Cancer: Overcoming IDO , 2013, Front. Immunol..
[16] S. Howng,et al. Plasma levels of transforming growth factor-beta 1 before and after removal of low- and high-grade astrocytomas. , 2013, Cytokine.
[17] Gelareh Zadeh,et al. Glioblastoma, a Brief Review of History, Molecular Genetics, Animal Models and Novel Therapeutic Strategies , 2012, Archivum Immunologiae et Therapiae Experimentalis.
[18] J. Graff,et al. Abstract C201: The combination of the small molecule TGFβR1 inhibitor LY2157299 monohydrate with CCNU substantially blocks SMAD phosphorylation and significantly suppresses human glioblastoma xenograft growth. , 2011 .
[19] M. Preusser,et al. IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. , 2011, Clinical neuropathology.
[20] G. D. de Bock,et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis , 2011, British Journal of Cancer.
[21] J. Baselga,et al. TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. , 2010, Cancer cell.
[22] David García-Dorado,et al. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. , 2009, Cancer cell.
[23] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[24] I. Türbachova,et al. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3+ conventional T cells , 2007, European journal of immunology.
[25] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[26] Alejandra Bruna,et al. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. , 2007, Cancer cell.
[27] W. Curry,et al. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma. , 2007, Cancer immunity.
[28] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[29] A. Friedman,et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. , 2006, Cancer research.
[30] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[31] M. Marques,et al. Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results. , 2003, Lung cancer.
[32] A Rimner,et al. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. , 2001, Cancer research.
[33] N. Sobol,et al. Preliminary results , 2020, Asymptotic Analysis of Random Walks: Light-Tailed Distributions.